AWI not OK with DNA

THE cost of DNA testing appears to be behind Australian Wool Innovation cutting off funds to its nucleus flock.

In a letter to its levypayers AWI said cost would deter DNA testing by stud breeders.

"The cost of genotyping is currently in the order of $130 and would have to drop to about $20 before a significant uptake is expected, " AWI chief executive Stuart McCullough and chairman Wal Merriman said in the letter.

Late last year AWI was asked to contribute $4.8 million to a nine-year program costing almost $13 million and involving a 6000-head flock joined over five years and four subsequent years of measurements.

At the time the Sheep Co-operative Research Centre paid $150 for a test that provided a parentage, detection of single gene traits such as pollness and predictions for a range of traits for wool and carcass quality, fertility and parasite resistance.

But Victorian Department of Primary Industries geneticist Dr Ben Hay said DNA costings were falling sharply worldwide.

Dr Hay said the cost of reading DNA had dropped by more than $100 in the past five years.

"And we can expect even greater reductions in the next couple of years," Dr Hay said.

Although AWI quoted a $130 test cost in its letter of last week, Sheep CRC chief executive Dr James Rowe said it had contracted a price of $110 for this year's pilot program and stud breeders would pay a subsidised rate of $50.

"We reckon it will be down to $50 next year," he said.

More here:
AWI not OK with DNA

Posted in DNA

Korle Bu DNA Centre to help unravel crimes

Health News of Tuesday, 3 July 2012

Source: Daily Graphic

The DNA Centre at the Korle-Bu Teaching Hospital says it has the facilities to assist the law enforcement agencies in the detection of crime.

It said its machines could determine the identity of criminals by extracting DNA from saliva, hair, blood, semen or any other bodily fluid left at a crime scene or on the victims by the perpetrators.

The Director of the centre, Dr Bartholomew Dzudzor, told graphic.com.gh that unfortunately, however, officials at the centre had not been trained in the collection of forensic samples from crime scenes, adding that the centre would be willing to partner the police if the police could perform that task.

He explained that during the commission of violent crimes, such as murder, kidnapping, rape, robbery, among other things, minute traces of blood and other bodily fluids, as well as hair, were left at the crime scene.

He said what was needed was well-trained forensic experts to carefully collect those samples, adding that extreme caution was essential to ensure that the samples were not contaminated.

According to him, DNA extracted from the samples would then be compared to the DNA of suspects and if they matched, the suspects could then be charged with the crime.

DNA may point at an individual and yet he or she may not be the perpetrator of the crime only if he or she was a homozygous (identical) twin, he said, adding that homozygous twins were formed from the same egg and, therefore, had similar DNA.

See original here:
Korle Bu DNA Centre to help unravel crimes

Posted in DNA

Global DNA Probes-Based Diagnostics Industry

NEW YORK, July 3, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Global DNA Probes-Based Diagnostics Industry

http://www.reportlinker.com/p098404/Global-DNA-Probes-Based-Diagnostics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnosti

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in US$ Million by the following Application Areas: Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Becton, Dickinson & Company, Beckman Coulter, Inc., bioMerieux, Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, QIAGEN, Roche Diagnostics, and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Infectious Diseases I-4Cancer I-4Genetic Predisposition I-4Identity/Forensics I-4Molecular HLA Testing I-4Other Diagnostic Applications I-4II. EXECUTIVE SUMMARY

1. MARKET DYNAMICS II-1

Industry Overview II-1

DNA Probes: Robust Growth Ahead II-1

Decoding the Genetic Puzzle II-1

Advantages of DNA-Probe Tests II-2

Go here to read the rest:
Global DNA Probes-Based Diagnostics Industry

Posted in DNA

Nutrition: Learning moderation is critical to a healthful diet

Mixed salted nuts are a better snack choice than sugary candy. (Craig F. Walker, Denver Post file)

It was dinnertime on the flight home from visiting family for two weeks. The stewardess offered the usual beverages ... juice, sodas, coffee.

Anything to eat? I inquired.

"Chips ... M&M's ... Chex Mix," she offered.

Note to self: Next time, remember to bring nuts and dried fruit for in-flight hunger pangs.

So as we bounced over the Rocky Mountains toward home, I was reminded that changes in routine often require flexibility especially with food. Maybe orange juice and Chex Mix isn't the best "dinner" I've ever had. But in the wise words of 16th-century bishop St. Francis de Sales: "A habitual moderation in eating and drinking is much better than certain rigorous abstinences made from time to time."

Moderation in eating and drinking. What an interesting concept.

My mind went back to the previous week's "Doggie Dash." It's an annual event hosted by my daughter's in-laws in their small midwestern town. Dogs of seemingly every size and breed walk with their owners through town while the local radio station plays songs such as "Hound Dog" and "How Much Is That Doggie in the Window?" When they arrive at the sponsoring veterinary clinic, the dogs are greeted with bandanas and bowls of fresh water, and the owners receive T-shirts and hot dogs.

"Isn't this a conflict of interest for you?" one of the veterinarians asked me as she eyed the lunch fare.

Not really. According to the position of the Academy of Nutrition and Dietetics, the most important focus of a healthful eating style is our "overall pattern" of eating. "All foods can fit within this pattern," says the Academy, "if consumed in moderation with appropriate portion size and combined with regular physical activity."

Excerpt from:
Nutrition: Learning moderation is critical to a healthful diet

Nutrition meets fine dining

Michelin-rated restaurant Rouge Tomate in New York City brings diners a modern twist on American cuisine.

Using SPE guidelines sourcing, preparation and enhancement the restaurant relies primarily on local ingredients to prepare its food. Executive Chef Jeremy Bearman and Executive Pastry Chef James Distefano works directly with culinary nutritionist, Kristy Lambrou, to provide a combination of fine dining and nutritious food at their restaurant.

The first Rouge Tomate opened in Brussels in 2001, explained Lambrou. The owner, Emmanuel Verstraeten, really wanted to show that nutrition and gastronomy could be combined and do not need to be mutually exclusive.

The philosophy of the restaurant follows the SPE charter, which Lambrou explains in Latin, sanitas per escam health through food. To ensure this philosophy flows throughout the menu, the chefs at Rouge Tomate do not add any butter or cream to appetizers or entrees and do not fry or grill any of the food.

"We want the guest to have about three servings of fruits and vegetables, Lambrou said So in order to do that we have criteria for each course; appetizers have to have a certain amount, entrees, and desserts."

Together Bearman, Distefano and Lambrou confer about combinations of ingredients, nutritional values and textures to ensure complete customer satisfaction. The chefs work with Lambrou to learn about the nutritional values of their dishes.

The first step of SPE is the S which stands for sourcing or where the products come from. The chefs first look for ingredients they want to use in their dishes that have beneficial nutrients, from local farmers and producers.

Once the specific ingredients are chosen, they decide how to prepare the food.

SPE is really taking these wonderful ingredients that we have and preparing them in a way that not only makes it taste really wonderful, but also keeps the nutritional integrity of the food, Bearman said. It is really important to us and really makes us different from a lot of other restaurants.

Finally, the restaurant pulls the different elements of the meal together before presenting it to the diner.

Read more:
Nutrition meets fine dining

UQ celebrates 50 years of microbiology

This week UQ is celebrating the 50th anniversary of the establishment of a Department of Microbiology, with an alumni dinner to be addressed by an eminent scientist working on polio a remerging disease.

Lectures in bacteriology were introduced to the UQ medical course in the late 1930s, the time of a polio epidemic in Australia.

The post-war years saw the evolution of teaching and research from clinical bacteriology to the wider discipline of microbiology.

Victor Skerman was appointed in 1950 and became the foundation professor of microbiology in 1962, heading the new Department of Microbiology.

The Department prospered over succeeding years, eventually moving from the University's Herston campus to a purpose-built building at St Lucia in 1972.

The building was renamed the Skerman Building in 1988, in honour of the man who led the departments of bacteriology and microbiology for 32 years.

Today, microbiology at UQ continues to prosper as part of the School of Chemistry & Molecular Biosciences.

Professor Ralph Tripp of the University of Georgia, USA, will present the annual Skerman Lecture on 5 July at Hillstone St Lucia.

He will speak on the development of enhanced vaccine cell lines for the eradication of poliovirus and other vaccine preventable diseases.

Despite a cessation of poliomyelitis in most areas of the world, outbreaks continue in nations where polio is endemic and in countries previously free of polio.

Read the original:
UQ celebrates 50 years of microbiology

DNA sequenced for parrot's ability to parrot

ScienceDaily (July 2, 2012) Scientists say they have assembled more completely the string of genetic letters that could control how well parrots learn to imitate their owners and other sounds.

The research team unraveled the specific regions of the parrots' genome using a new technology, single molecule sequencing, and fixing its flaws with data from older DNA-decoding devices. The team also decoded hard-to-sequence genetic material from corn and bacteria as proof of their new sequencing approach.

The results of the study appeared online July 1 in the journal Nature Biotechnology.

Single molecule sequencing "got a lot of hype last year" because it generates long sequencing reads, "supposedly making it easier to assemble complex parts of the genome," said Duke University neurobiologist Erich Jarvis, a co-author of the study.

He is interested in the sequences that regulate parrots' imitation abilities because they could give neuroscientists information about the gene regions that control speech development in humans.

Jarvis began his project with collaborators by trying to piece together the genome regions with what are known as next-generation sequencers, which read chunks of 100 to 400 DNA base pairs at a time and then take a few days to assemble them into a draft genome. After doing the sequencing, the scientists discovered that the read lengths were not long enough to assemble the regulatory regions of some of the genes that control brain circuits for vocal learning.

University of Maryland computational biologists Adam Phillippy and Sergey Koren -- experts at assembling genomes -- heard about Jarvis's sequencing struggles at a conference and approached him with a possible solution of modifying the algorithms that order the DNA base pairs. But the fix was still not sufficient.

Last year, 1000 base-pair reads by Roch 454 became available, as did the single molecule sequencer by Pacific Biosciences. The Pacbio technology generates strands of 2,250 to 23,000 base pairs at a time and can draft an entire genome in about a day.

Jarvis and others thought the new technologies would solve the genome-sequencing challenges. Through a competition, called the Assemblathon, the scientists discovered that the Pacbio machine had trouble accurately decoding complex regions of the parrot, Melopsittacus undulates, genome. The machine had a high error rate, generating the wrong genetic letter at every fifth or sixth spot in a string of DNA. The mistakes made it nearly impossible to create a genome assembly with the very long reads, Jarvis said.

But with a team, including scientists from the DOE Genome Science Institute and Cold Spring Harbor in New York, Phillippy, Koren and Jarvis corrected the Pacbio sequencer's errors using shorter, more accurate codes from the next-generation devices. The fix reduces the single-molecule, or third-generation, sequencing machine's error rate from 15 percent to less than one-tenth of one percent.

Go here to read the rest:
DNA sequenced for parrot's ability to parrot

Posted in DNA

Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

Geneva, Switzerland, 3 July 2012 - Addex Therapeutics(ADXN.SW), a leading company pioneering allosteric modulation-based oral small molecule drug discovery and development, announced today the appointment of Dr. Graham Dixon to the newly created position of Chief Scientific Officer and Head of Research. Dr. Dixon will report directly to Dr. Bharat Chowrira, CEO of Addex, and will be responsible for leading all aspects of research and non-clinical development activities at Addex.

"We are delighted to have Graham join the Addex team. Graham has a strong background and an impressive track record in small molecule pharmaceutical research and development. He has been responsible for the discovery of novel drugs and steering their development from basic science into clinical development, as well as bringing products through mid-stage proof-of-concept clinical trials." stated Dr. Bharat Chowrira, CEO of Addex. "Addex` strength lies in our leading allosteric modulation technology and the ability to leverage this platform to develop drug candidates against previously undruggable but important validated biological targets. Graham`s experience and R&D leadership will be instrumental as we execute on our core strategy and continue to build a robust proprietary pipeline of high value drug discovery and development programs and rapidly advancing these drug candidates towards the clinic"

Dr. Dixon joins Addex with more than 20 years of experience in pharmaceutical researc, most recently as Chief Scientific Officer at Galapagos NV. In this role, Dr. Dixon was responsible for all research & early development within the company in multiple therapeutic areas as well as the management of more than 260 scientific personnel across three sites in the Netherlands, Belgium and France. Prior to Galapagos, Dr. Dixon was Chief Scientific Officer at Entomed SA, a developer of natural anticancer and anti-infective agents. Dr. Dixon joined Entomed from a similar role at antifungal therapeutic company, F2G Ltd. Before joining F2G, Dr. Dixon held several roles at AstraZeneca starting as a project manager in anti-infective research and culminating in the role of Global Product Director in the oncology division. He started his career as Head of Biochemistry at Dowelanco (UK) Ltd. Dr. Dixon earned his PhD in biochemistry from the University of Swansea and a BSc in applied biology from the University of Bradford.

"I am excited about joining Addex, the recognized industry leader in allosteric modulation-based oral small molecule drug discovery and development," said Dr. Dixon. "I look forward to building on the significant progress made by the world-class scientists at Addex and applying this powerful platform towards creating an attractive engine of innovative product candidates for the treatment of serious diseases and indications with a huge unmet medical need."

Addex Therapeutics (www.addextherapeutics.com) discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company`s two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson`s disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by Addex` partner Janssen Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in patients suffering from major depressive disorder. Addex also is advancing several preclinical programs including: GABA-BR PAM for overactive bladder, pain and other disorders; mGluR4 PAM for Parkinson`s, MS, anxiety and other diseases; GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer`s disease and depression. In addition, Addex has discovery programs to identify allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer`s, Parkinson`s and Huntington`s diseases); and TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.

Mike Sinclair Halsin Partners Tel: +44 30 7318 2955 msinclair(at)halsin.com

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management`s expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company`s ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Addex Therapeutics via Thomson Reuters ONE HUG#1623513

See original here:
Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

MU Researcher Receives NIH MERIT Award

COLUMBIA The bacterium Escherichia coli (E. coli) has a rudimentary molecular "memory" that allows it to swim toward the richest sources of food. MU biochemistry professor Gerald Hazelbauer's discoveries about bacteria could shed light on human and animal sensory, memory and response systems.

"When I began my work as a researcher in the late 1960s, studying bacterial behavior was a curiosity and its significance unclear," Hazelbauer said. "Now, decades later, the research done by my group and others has grown into a body of knowledge about the fundamental processes used by all living things to recognize, remember and respond to changes in their environments."

The National Institute of General Medical Sciences (NIGMS) recently recognized and rewarded Hazelbauer's scientific contributions by granting him a "Method to Extend Research in Time" (MERIT) Award. The award, which is worth at least $5.5 million over 10 years, will allow him to continue his research without re-applying for funding. Hazelbauer joins only 11 other MU researchers who have received the MERIT award, including his wife, Linda Randall, who is also a biochemistry professor.

MERIT awards are intended to foster creativity and allow researchers to take more time to develop new techniques.

The awards are given only to scientists who have proven themselves by succeeding in at least 10 years of previous NIGMS-funded research and who seem likely to continue making valuable contributions to their field.

Read more:
MU Researcher Receives NIH MERIT Award

Anatomy of a farce: rights and the wrongs of a DJ dalliance

The withdrawal of a $1.65 billion takeover bid for national retailer David Jones has bought to a close one of the most bizarre chapters in the companys 174-year history.

In our step-by-step analysis of the bidmade by little-known private equity company EB Private Equitywe unravel the complexities facing David Jones chair Bob Savage, his board and management.

The takeover bid

On May 28, the David Jones board received an email, dated May 22, with an unconditional but incomplete bid for the company. According to The Australian Financial Review, David Jones chairman Bob Savage thought the deal didnt feel right. He emailed the bidder asking for more information. It would be a month before he received any response.

The bidder was John Edgar, representing EB Private Equity, a private equity group that claims to have a focus on property.

The David Jones board was faced with three possibilities: saying nothing until further details were forthcoming; making an announcement; or going into a trading halt.Usually, you would expect the board to quickly make an announcement about a bid, says the chief executive of Chartered Secretaries Australia, Tim Sheehy.

My hunch is that they hesitated because they had doubts about the legitimacy of the bid, he told LeadingCompany. In a perfect world where a bid came through a well-known, recognised investment bank, and was legitimate, they would have to disclose relatively quickly. This one didnt seem bona fide from the start, and they set about investigating.

The David Jones board was under no obligation to reveal the bid by EB Private Equity, says professor Ian Ramsay, director of the centre for corporate law and securities regulation at Melbourne University. Ramsay was responsible for the review that led to changes in corporate law in 2004 in the wake of corporate collapses such as HIH insurance in 2001.

The ASX requires under listing rules disclosure of material information [that will affect the share price], but there is a carve out and that includes an incomplete proposal, he said.

On June 28, a day before David Jones finally revealed the offer, EB Private Equity responded to Savages request for more information. The email contained few new details about the bidder, but did update the offer to $1.65 billiona 40% premium on the companys then market value.

See the rest here:
Anatomy of a farce: rights and the wrongs of a DJ dalliance

Generating dopamine via cell therapy for Parkinson’s disease

Public release date: 2-Jul-2012 [ | E-mail | Share ]

Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation

In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's disease patients, such cell therapy options must still overcome technical obstacles before the approach is ready for the clinic. Embryonic stem cell-based transplantation regimens carry a risk of introducing inappropriate cells or even cancer-prone cells. To develop cell purification strategies to minimize these risks, Dr. Lorenza Studer and colleagues at Memorial Sloan Kettering Cancer Center in New York developed three different mouse lines to fluorescently label dopaminergic neurons at early, mid, and late stages of differentiation. Their data suggest that mouse embryonic stem cells induced to the mid stage of neuronal differentiation are best suited for transplantation to replace dopaminergic neurons. Further, their work identified new genes associated with each stage of neuronal differentiation. Their results in the mouse model system help define the differentiation stage and specific attributes of embryonic stem cell-derived, dopamine-generating cells that hold promise for cell therapy applications.

###

TITLE:

Identification of embryonic stem cellderived midbrain dopaminergic neurons for engraftment

AUTHOR CONTACT:

Lorenz Studer

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Phone: 212.639.6126; E-mail: studerl@mskcc.org

Read more here:
Generating dopamine via cell therapy for Parkinson's disease

Amicus Therapeutics Announces Publication of BLISS Quantitative Histology Method in Archives of Pathology & Laboratory …

CRANBURY, N.J., July 2, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced that a manuscript describing the Barisoni Lipid Inclusion Scoring System (BLISS) has been published in the July 2012 issue of Archives of Pathology & Laboratory Medicine. The manuscript titled, "A Novel, Quantitative Method to Evaluate GL-3 Inclusions in Renal Peritubular Capillaries by Virtual Microscopy in Patients with Fabry Disease,"1 is currently available online.

BLISS improves the ability to detect and quantify changes in globotriaosylceramide (GL-3) peritubular capillary (PTC) inclusions - also referred to as interstitial capillaries - in females and males with Fabry disease. GL-3 is the lipid substrate that accumulates in tissues affected by Fabry disease, including the kidney. BLISS was developed by Dr. Laura Barisoni while she was an Associate Professor in Pathology and Medicine at the New York University School of Medicine, in collaboration with Amicus. Dr. Barisoni is currently a Voluntary Associate Professor in Pathology at the University of Miami.

In a Phase 3 study (Study 011) intended for U.S. registration of migalastat HCl monotherapy for Fabry disease, BLISS with virtual microscopy will be utilized for the histological evaluation of interstitial capillary GL-3 in kidney biopsies, the primary endpoint. Migalastat HCl is an oral investigational pharmacological chaperone for Fabry disease being developed by Amicus in collaboration with GlaxoSmithKline (GSK).

Previous pivotal studies of enzyme replacement therapy (ERT) for Fabry disease used a semi-quantitative approach with conventional light microscopy. Pathologist readers manually searched for and categorically scored PTC GL-3 (0, 1, 2, or 3) within the same histological sections, but not necessarily in the same PTCs. A more sensitive methodology was needed to more accurately and reliably quantify GL-3 inclusions, and to assess response to treatment, particularly in patients who have lower amounts of GL-3.

Published Results

The study published by Dr. Barisoni and colleagues compared BLISS to the previously reported semi-quantitative scoring method. Intra- and inter-reader variability was also assessed using BLISS in combination with virtual microscopy (BLISS-VM) versus conventional light microscopy (BLISS-LM). The novel BLISS-VM protocol was created by the pathology team composed of Dr. Barisoni; Dr. Charles Jennette, Professor and Chair at the University of North Carolina-Chapel Hill; and Dr. Robert Colvin, Professor in Pathology at the Massachusetts General Hospital.

Pre-treatment kidney biopsies were scored from 17 patients (eight males and nine females) enrolled in three Phase 2 studies of migalastat HCl. Results demonstrated that BLISS is a more sensitive scoring system to measure GL-3 inclusions in PTCs compared to the semi-quantitative methodology. The addition of virtual microscopy further improved accuracy and reproducibility of BLISS, reducing intra- and inter-reader variability. BLISS-VM used one pathologist annotator to identify PTCs on a scanned digital slide image, and different pathologist readers to score the total number of GL-3 inclusions in each PTC identified by the annotator. The annotation step ensures that both readers are scoring the same PTCs. Results are digitally recorded as each PTC is scored to prevent double counting. The scored digital images also provide a permanent and retrievable record for clinical studies and submission to regulatory authorities.

Dr. Barisoni stated, "We developed BLISS as a novel quantitative methodology to detect GL-3 in both male and female Fabry patients. Our study showed that BLISS was able to detect GL-3 inclusions that were missed by the semi-quantitative scoring method. While the traditional semi-quantitative methodology can measure GL-3 inclusions in patients with a high level of GL-3 storage, a large percentage of Fabry patients have some residual enzyme activity and fewer GL-3 inclusions. In addition, innovations in digital imaging have made it possible to incorporate virtual microscopy to address several limitations of conventional light-based microscopy."

Drs. Barisoni, Jennette, and Colvin will utilize BLISS-VM to score the kidney biopsies of Fabry patients in Study 011. Amicus and GlaxoSmithKline (GSK) are on track to report results from this study in the third quarter of 2012.

1. Barisoni L.1, Jennette J.C.2, Colvin R.3, Sitaraman S.4, Bragat A.4, Castelli J.4, Boudes P.4, Archives of Pathology & Laboratory Medicine: July 2012, Vol. 136, No. 7, pp. 816-824.

More here:
Amicus Therapeutics Announces Publication of BLISS Quantitative Histology Method in Archives of Pathology & Laboratory ...

Nationwide Planting of Vegetables in Schools Kicks-Off Nutrition Month Celebration

July 2 marks the official start of this years Nutrition Month celebration guided by the theme Pagkain ng gulay ugaliin, araw-araw itong ihain!. The National Nutrition Council of the Department of Health kicks-off the nationwide celebration with the planting of vegetables by school children of the ConcepcionElementary Schoolin Marikina City.

The children will be joined by Health Secretary and NNC Chair Enrique Ona, Agriculture Secretary Proceso Alcala, Social Welfare Secretary Dinky Soliman and Education Secretary Armin Luistro together with NNC Executive Director and concurrent Assistant Secretary of Health Maria-Bernardita Flores.

Thousands of school children are expected to plant vegetables in public elementary schools. The Department of Education issued a memorandum encouraging all schools to celebrate Nutrition Month with the simultaneous planting of vegetables as part of its share to promote consumption of vegetables among children as part of a healthy diet.

This years Nutrition Month celebration aims to encourage every Filipino to eat more vegetables, i.e. 3 servings or more per day, to add more vitamins and minerals in the diet as well as prevent non-communicable diseases such as various forms of cancer, cardiovascular disease and diabetes. As vegetables have less calories, adding them to the diet can help people to reduce weight or maintain normal body weight. A serving of vegetable is equal to a cup of raw leafy vegetables or cup of raw or cooked non-leafy vegetables.

The campaign is in response to the finding that the average Filipino eats less and less vegetables per day in the past 30 years. Based on the food consumption surveys of the Food and Nutrition Research Institute, Filipinos eat only about 2 servings of vegetables on average or about 110 grams. The vegetable consumption has been declining since 1978 when Filipinos still ate 145 grams per day. The data is alarming considering that low fruit and vegetable intake is among the top 10 selected risk factors for global mortality based on a World Health Organization Report. The report also showed that 1.7 million deaths are due to low intake of fruits and vegetables.

The Nutrition Month campaign also aims to encourage families, schools and communities to put up vegetable gardens to ensure supply of fresh and nutritious vegetables. The FNRI also reported that only 67.7% of Filipino households have vegetable gardens or fruit trees. Having vegetable gardens can help in reducing malnutrition and hunger especially among poor families.

According to A/Sec. Flores, The NNC encourages everyone to consume three or more servings of vegetables each day. Lets also eat our indigenous vegetables such as malunggay, saluyot, kangkong, kamote tops and ampalaya. Let us also plant vegetables in all possible places. Even if there is no available space in many urban communities, , there are many urban gardening technologies such as container gardening and the use of hydroponics or soil-less gardening that can be used.

A/Sec Flores also added that Young infants starting at 6 months, should be given pureed, mashed and finely cut green leafy and yellow vegetables. This can be added to thick lugaw to make for a nutritious complementary food in addition to breastmilk. The NNC is very concerned that infants 6-11 months old had an intake of only 2 grams of vegetables while 1 year old children had an intake of 8 grams per day on average. For young children, vegetables are important sources of vitamin A and iron which are important nutrients that improve childrens immune system, growth and development.

Other government agencies, non-government organizations, local government units, private sector and civil society are expected to also conduct various activities to help in promoting vegetables consumption.

See the original post here:
Nationwide Planting of Vegetables in Schools Kicks-Off Nutrition Month Celebration

Schiff Nutrition Appoints Richard F. Baruch Jr. Senior Vice President – Chief Commercial Officer

SALT LAKE CITY--(BUSINESS WIRE)--

Schiff Nutrition International, Inc. (SHF) appointed, effective today, Richard F. Baruch Jr., 44, to the new position of Senior Vice President Chief Commercial Officer.

Rich brings an extensive background in sales, marketing and general management, and we welcome him to the team, stated Tarang Amin, president and chief executive officer of Schiff Nutrition. With over 20 years of experience expanding brands and delivering results at leading companies such as Coca-Cola, Clorox, and Procter & Gamble, we believe Rich will help broaden our commercial opportunities.

Baruch stated: I am excited to join Schiff and I believe my skill set complements Schiffs strong leadership team. Together, we can drive further growth, particularly in our efforts to expand the channel and geographic footprint of the company.

Baruch most recently served as Vice President Category Advisory Services at Coca-Cola where he led an initiative to build a new organization and bring a new set of capabilities to Coca-Colas North American business. Prior to that, Baruch was President and Chief Operating Officer of CotnWash, Inc. where he led the national launch of Dropps laundry detergent and grew overall top-line revenue by over 300% over two years. Previously, Baruch spent fourteen years at The Clorox Company in a number of leadership roles, with the most recent being Vice President and General Manager of the Home Care business. He began his career at Procter & Gamble in various sales management roles. Baruch holds a bachelors degree from the University of Pennsylvania.

About Schiff Nutrition

Schiff Nutrition International, Inc. is a leading nutritional supplement company offering vitamins, nutritional supplements and nutrition bars in the United States and abroad. Schiffs portfolio of well-known brands includes Move Free, MegaRed, Airborne, Tiger's Milk, Sustenex, Digestive Advantage and Schiff Vitamins. Focused on quality for 75 years, Schiffs headquarters and award-winning manufacturing and distribution facility are based in Salt Lake City, Utah. To learn more about Schiff, please visit the web site http://www.schiffnutrition.com.

See the article here:
Schiff Nutrition Appoints Richard F. Baruch Jr. Senior Vice President - Chief Commercial Officer

What Diving Seabirds Can Tell Us About Our Own Longevity

July 2, 2012

[ Watch the Video ]

redOrbit Staff & Wire Reports Your Universe Online

Diving seabirds reach their 30s and then die swiftly and unexpectedly, showing little signs of aging prior to their death. Studying these birds could help us understand the aging process and provide critical insights for our aging citizens.

Researchers studied Guillemots which look similar to penguins but can fly over four summers. During this time, they periodically tracked Brnnichs guillemots fitness, recording depth and for how long they would dive for prey, how far and fast they would fly, and how much energy they used on these activities. They also looked for changes in the birds behavior and metabolism.

Guillemots have the highest flight outlay of any bird and use large amounts of energy for diving. Their high metabolisms and frequent dives should produce oxidative stress, causing the birds to weaken as they age. However, the researchers discovered that the birds stay fit and active as they grow older, maintaining their flying, diving, and foraging abilities.

Kyle Elliott, a PhD student at the University of Manitoba and the studys lead author, said, Most of what we know about aging is from studies of short-lived round worms, fruit flies, mice, and chickens, but long-lived animals age differently. We need data from long-lived animals, and one good example is long-lived seabirds.

Elliott also said, Not only do these birds live very long, but they maintain their energetic lifestyle in a very extreme environment into old age.

One bird, nicknamed Wayne Gretzky by the researchers (after the Canadian hockey great who played 20 seasons and because the birds band of colors matched Gretzkys team colors), raised young for 18 uninterrupted years.

The findings will be presented today at the Society for Experimental Biology meeting in Salzburg.

See the original post here:
What Diving Seabirds Can Tell Us About Our Own Longevity

DNA Results Negative For Angeline Quinto, Purported Mother

The key to Angelines true identity remains elusive (File Photo)

MANILA, Philippines It seems singer Angeline Quintos quest to find her biological mother has not yet come to an end.

Although frustrated and emotional after the recent DNA test she underwent together with Veronica Tolentino, the woman claiming to be her biological mom, came back negative, Quinto vowed to continue searching for her real mother.

Sabi ko nga po sa tatay ko, tulungan niyo rin naman po ako na sana may magawa rin siya para makita namin ang totoo kong nanay, Quinto shared in a taped interview with The Buzz aired on July 1.

Aside from Tolentino, Quintos father Pop Quiros, also subjected himself to a DNA testing. Unlike Tolentino, the test yielded a positive result for Quiros, which means that shes Quintos biological father.

Natutuwa po ako na si Papa ko talagang tatay ko po at siyempre 'yung mga nakilala ko po na mga kapamilya ko simula noong bata ako, talagang kapamilya ko po, she said.

However, Quinto, for her part, felt sorry that she got a negative result when her DNA was cross-examined with Tolentinos.

Nakita niyo naman po kung ano ang reaction ni Aling Veronica, talagang umiyak siya noong niyakap niya ako. Sabi ko nga po, Pasensya na po kayo, siguro po ganoon talaga, the singer recalled.

Feeling for Tolentino, Quinto related that shes praying for her to eventually find her own biological daughter whom shes been searching for, for so long.

As for her own search, Quinto vowed that this is not the end; just the beginning of yet another chapter.

Originally posted here:
DNA Results Negative For Angeline Quinto, Purported Mother

Posted in DNA

Humble DNA could help decipher dark matter

A few strands of DNA could help solve the mystery of dark matter. A newly proposed detector aims to use DNA to resolve the conflicting claims from current dark matter detectors.

Dark matter is thought to make up about 85 per cent of the matter in the universe. The prime suspects are so-called weakly interacting massive particles, which are immune to the electromagnetic and strong nuclear forces. In theory, WIMPs interact with normal matter only via gravity and the weak nuclear force.

Attempts to detect WIMPs on Earth have provided conflicting results. On the positive front, two experiments CoGeNT in Soudan, Minnesota, and DAMA/LIBRA at Gran Sasso, Italy have seen more putative dark matter particles hitting their detectors in June than in December. All else being equal, the excess is attributed to Earth's relative velocity through the sea of dark matter that fills our galaxy. In June, Earth is moving in the same direction as the sun and so encounters a "headwind" of dark matter, the theory goes. In December, Earth, in its orbit around the sun, is moving in the opposite direction.

But, crucially, other bigger and more sensitive experiments, such as CDMS-II and XENON1O0, have seen no such particles. One way to resolve the conflict would be to detect the directionality of dark matter particles, to see if they are indeed aligned with the direction of the sun's motion through the galaxy, as required by DAMA/LIBRA and CoGeNT.

Now Andrzej Drukier of Biotraces a biotech firm based in Herndon, Virginia and a group of cosmologists and biochemists are suggesting that DNA could help break the impasse.

Their proposed detector consists of a 1-metre-square sheet of gold foil and a "forest" of single-strand DNA molecules suspended beneath in an ordered array, like the bristles on a toothbrush. When a WIMP strikes a gold atom in the foil, it would dislodge a gold nucleus and send it careening through the array, severing the DNA strands along its path. Energetic particles like cosmic rays have been shown to collide with and break strands of DNA, though WIMPs would have much lower energy.

The broken DNA strands would be gathered, amplified and analysed to determine exactly where each strand was severed. Given that the sequence of bases that make up each DNA strand is well known, the location of the cut on each strand and hence the path of the gold nucleus could be tracked to within a nanometre in three dimensions, around 1000 times better resolution than current detectors.

"The higher resolution means that we would get more data per WIMP event," says team member George Church of Harvard University.

Such 3D resolution would allow cosmologists to infer the both the energy and the direction of a WIMP, which could in turn confirm the existence of the predicted "WIMP wind" created by the solar system's motion through the galaxy.

A DNA-based detector has other advantages too, the team claims. It can operate at room temperature, as opposed to near absolute zero for current detectors. And by changing the material of the foil, it can be tuned to look for particles of different energies, including the WIMPs apparently detected by CoGeNT and DAMA/LIBRA. The team is now testing the feasibility of the design.

Read more from the original source:
Humble DNA could help decipher dark matter

Posted in DNA

How A 'DNA Tracking Chamber' Could Detect Dark Matter

Perhaps the greatest and most fiercely contested race in modern science is the search for dark matter.

Physicists cannot see this stuff, hence the name. However, they infer its existence because they can see its gravitational influence on the structure of galaxies and clusters of galaxies. It implies that the universe is filled with dark matter, much more of it than the visible matter we can see

If they're right, dark matter must fill our galaxy and our Solar System. At this very instant, we ought to be ploughing our way through a dense sea of dark matter as the Sun moves towards the constellation of Cygnus as it orbits the galactic centre.

That's why various groups are racing to detect this stuff using expensive detectors in deep underground caverns, which shield them from radiation that would otherwise swamp the signal.

These experiments are looking for the unique signature that dark matter is thought to produce as a result of the Earth's passage around the Sun. During one half of the year, the dark matter forms headwind as the Earth ploughs into it; for the other half of the year, it forms a tailwind.

Indeed, a couple of groups claim to have found exactly this diurnal signature, although the results are highly controversial and seem to be in direct conflict with other groups who say they have not seen it.

There's a a straightforward way to make better observations that should solve this conundrum. The dark matter signal should vary, not just over the course of a year, but throughout the day as the Earth rotates.

The dark matter headwind should be coming from the direction of Cygnus, so a suitable detector should see the direction change as the Earth rotates each day.

There's a problem, however: nobody has built a directional dark matter detector.

That's why a revolutionary new idea from an unlikely collaboration of physicists and biologists looks rather exciting. The group brings together diverse people, such as Katherine Freese at the University of Michigan in Ann Arbor, an astrophysicist and one of the leading thinkers in the area of dark matter, and George Church at Harvard University in Cambridge, a geneticist and a pioneer in the area of genome sequencing.

Link:
How A 'DNA Tracking Chamber' Could Detect Dark Matter

Posted in DNA

Revolutionary 'DNA Tracking Chamber' Could Detect Dark Matter

Perhaps the greatest and most fiercely contested race in modern science is the search for dark matter.

Physicists cannot see this stuff, hence the name. However, they infer its existence because they can see its gravitational influence on the structure of galaxies and clusters of galaxies. It implies that the universe is filled with dark matter, much more of it than the visible matter we can see

If they're right, dark matter must fill our galaxy and our Solar System. At this very instant, we ought to be ploughing our way through a dense sea of dark matter as the Sun moves towards the constellation of Cygnus as it orbits the galactic centre.

That's why various groups are racing to detect this stuff using expensive detectors in deep underground caverns, which shield them from radiation that would otherwise swamp the signal.

These experiments are looking for the unique signature that dark matter is thought to produce as a result of the Earth's passage around the Sun. During one half of the year, the dark matter forms headwind as the Earth ploughs into it; for the other half of the year, it forms a tailwind.

Indeed, a couple of groups claim to have found exactly this diurnal signature, although the results are highly controversial and seem to be in direct conflict with other groups who say they have not seen it.

There's a a straightforward way to make better observations that should solve this conundrum. The dark matter signal should vary, not just over the course of a year, but throughout the day as the Earth rotates.

The dark matter headwind should be coming from the direction of Cygnus, so a suitable detector should see the direction change as the Earth rotates each day.

There's a problem, however: nobody has built a directional dark matter detector.

That's why a revolutionary new idea from an unlikely collaboration of physicists and biologists looks rather exciting. The group brings together diverse people, such as Katherine Freese at the University of Michigan in Ann Arbor, an astrophysicist and one of the leading thinkers in the area of dark matter, and George Church at Harvard University in Cambridge, a geneticist and a pioneer in the area of genome sequencing.

Visit link:
Revolutionary 'DNA Tracking Chamber' Could Detect Dark Matter

Posted in DNA

DNA Methylation Linked to Memory Loss

Scientists find that declining DNA methylation in mouse neurons may cause age-related memory deficits.

Researchis increasingly connecting changes in epigenetic regulation of gene expression to the aging process. Many studies demonstrate that DNA methylation declines with age. Now, new research published yesterday (July 1) in Nature Neuroscience links DNA methylation with brain aging. Researchers show that levels of an enzyme that attaches methyl groups to cytosine nucleotides throughout the genome is linked to cognitive decline, and that its overexpression can restore performance of aging mice on memory-related tasks.

We already know normal aging is associated with cognitive decline, but this paper links that with expression a specific DNA methyltransferase, said Yuan Gao, an epigeneticist at the Lieber Institute for Brain Development in Maryland, who did not participate in the study. The current work also builds on other studies demonstrating that proper regulation of methylation in brain cells is critical to memory formation. Previous studies have suggested a connection between loss of DNA methylation and Alzheimers disease, said Gao, suggesting that if researchers could restore [methyltransferase] activity and cure or delay dementia, it would make a nice model for developing drugs to tackle age-related cognitive diseases.

DNA methylation, wherein a methyl group is attached to a cytosine next to a guanosine, is one form of epigenetic regulation that can modulate how available genes are to the cells transcription machinery, and thus how highly expressed they are. Scientists already appreciate how differences in epigenetic regulation can affect development of diseases like cancer, without need for gene mutations. Studies are also accumulating that correlate declining methylation with aging, although the mechanism remains unclear.

Classically, DNA methylation is considered a repressive modification, but that view is beginning to change, suggesting a more nuanced role for methylation in gene regulation, explained senior author Hilmar Bading of the University of Heidelberg. The twist in Badings current research is that the methyltransferase his group focuses on, Dnmt3a2, may be working to enable gene transcription, rather than repress it.

This gene-activating role may stem from methylation that blocks repressors, rather than activators, explained Trygve Tollesfbol, who investigates the role of epigenetics in cancer and aging at the University of Alabama, who did not participate in the research. Whether methylation is located in the promoter or body of the gene can also determine whether it inhibits or enhances transcription, explained Guoping Fan, who studies epigenetic regulation of neuron development at the University of California, Los Angeles.

Badings group identified Dnmt3a2 when looking for genes that are upregulated by neuronal activity. Knowing that DNA methylation decreases with age, first author Ana Oliviera compared Dnmt3a2 expression in 3-month-old and 18-month-old mice, and found lower levels of Dnmt3a2 in the older mice. Furthermore, learning tasks designed to stimulate hippocampus neurons failed to upregulate Dnmt3a2 expression in old mice as robustly as in young mice.

Theorizing that reduced Dnmt3a2-dependent DNA methylation contributed to older mices poorer performance on learning and memory tasks, the scientists used an adeno-associated virus to supplement Dnmt3a2 expression in their hippocampal neurons. Boosting its expression enhanced both brain methylation in the older mice, and their ability to learn. Conversely, when the researchers used short hairpin RNA to knockdown Dnmt3a2 expression in young mice, their performance on learning and memory tests worsened.

I think Dnmt3a2 has a basic gating function, said Bading. Neurons need to turn genes on and off quickly in response to changing stimulation. Bading hypothesizes that Dnmt3a2-dependent methylation helps keep geneslike brain-derived neurotrophic factor (BDNF) and Arc, both regulated by Dnmt3a2 and both involved in responses to signaling changesreceptive to changing stimulation, putting the genome in the right state for being inducible, Bading said. Genes like BDNF shouldnt be transcribed all the time, but it may be that without Dnmt3a2-dependent methylation, the door is closed neurons cant express them when they need to.

This could set up a vicious cycle, Bading explained, because Dnmt3a2 is also induced by neuronal activity. Less Dnmt3a2 would result in less expression of methylation-dependent genes, possibly including Dnmt3a2 itself, and the effect would worsen over time. It would take many years to add up, but aging takes years, Bading noted.

Go here to read the rest:
DNA Methylation Linked to Memory Loss

Posted in DNA